ARTICLE | Product Development
Plus readouts for Nanoscope, Axsome, Chugai, Acelyrin and Nkarta
By Paul Bonanos and Stephen Hansen, Directors of Biopharma Intelligence
March 26, 2024 9:05 PM UTC
Updated on Mar 26, 2024 at 10:45 PM UTC
Clinical catalysts drove big market cap gains this week, with Viking, Stoke and Praxis each reporting news ahead of Tuesday’s trading session that lifted shares by double-digit percentages.
The latest boon for Viking Therapeutics Inc. (NASDAQ:VKTX) was a Phase I readout showing that the top dose its oral version of GLP-1/GIPR agonist VK2735 led to mean placebo-adjusted weight loss of 3.3% at day 28 in a Phase I study. Last month, Viking said its subcutaneous version of the product led to 13.1% placebo-adjusted weight loss after 13 weeks, positioning the company as a potential takeout target for a pharma seeking to break into the obesity arena and doubling its share price…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651912/clinical-report-catalysts-drive-up-shares-of-viking-stoke-praxis